In the metastatic setting of HER2-positive esophagogastric adenocarcinoma (EGA), the ToGA trial demonstrated that adding the HER2-targeting antibody trastuzumab to chemotherapy significantly improves survival compared to chemotherapy alone5. The gene discussed is ERBB2; the disease is gastroesophageal junction adenocarcinoma.